Stan Gable
Well-known member
Optical networking stocks are getting crushed lately. Picking up some JDSU and FNSR for the long run.
Optical networking stocks are getting crushed lately. Picking up some JDSU and FNSR for the long run.
i think optical networking stock were overbought back at the beginning of the year. most of these stocks are up 30% on a one year basis.
and jdsu is selling at a crazy 60:1 p/e
Silver over the next year--SLV---bad US economy, plus growing industrial use. US credit rating takes a Moody's hit in August, watch the metals
ANd over the next couple of years, SIRI--Sirius Radio looks to have righted the ship and has a good looking chart, which if it keeps it up [ going from .50 to $2.50 over the last 6 months ], looks to be a nice $4 to $8 stock in the next couple of years.
Expenses are in line & growth to other countris is a definite possibility.
200 moving day average for the S&P is at 1,250 so I'm thinking stocks have a bit further to fall and they will test this number and maybe go lower. Last year stocks had a great run starting in late August/early September so for now my plan is to buy some more around that time this year.
I love biotech and own the exchange fund FBT. The whole industry is too arcane and speculative for my tiny brain so I do not want to buy stock in any specific company. But there are so many developments that seem to come out of biotech that I wanted to own a diverse fund and I plan on holding it for the long haul.
What is hESC?
Investing in a fund is definitely the safer way to play it. Personally, I've just bought in to a couple of different stocks in the space and plan on holding onto them long term with the understanding that most will probably flame out.
I'm particularly interested in stem cells, so I'm holding onto a number of different players here (GERN, BTX, ACTC.OB, ISCOE.OB, etc.). hESC stands for human embryonic stem cells (the controversial kind vs. the less controversial adult stem cells and induced pluripotent stem cells).
Advanced Cell Technology is by far my biggest position and it is only the second company to receive FDA approval for phase 1 trials using hESC's (the first being Geron). Where it differs from Geron is that rather than trying to tackle something like spinal cord injuries, they are focused on what their old CEO referred to as their "low-hanging fruit strategy." They are developing therapies in hopes of curing AMD and SMD, two of the leading causes of blindness. The benefit here is that the eye is immune privileged (meaning the body is less likely to reject the foreign cells), the market is huge (I read somewhere that J&J called it the largest unmet medical need in the world), and that results will be evident relatively quickly compared to most therapies.
They were in an absolutely horrible place financially the past few years, but seem to have turned the corner of course at the expense of massive dilution. The good news is they are ready to move forward with injections, which will be done by the end of June according to their latest conference call and that they are expecting preliminary results to be released by October/November timeframe. Best case scenario being positive early results that will allow them to JV with a larger pharma from a position of strength.
Obviously biotech/pharma investments are extremely speculative, but I tend to believe in the science and the animal models that have been explored thus far. If even one of these companies proves successful in humans, I think general government, religious, and financial approval will follow.
Really this new IPO craze is getting out of hand. Pandora valued at $2 billion off of $138 million in revenue and 1% EBITDA margins? Jesus Christ.
Don't know why I didn't respond to this, because it's a good post. I think 1250 will be tested very soon. I actually think you're going to wind up seeing 100-150 points below that by September. Stocks are still relatively cheap if you look at current versus average P/E ratios. You have to have a chart that can let you do that with *current* companies in the S&P 500 since many in the long term charts aren't even in the S&P any more.